RE: safety profile and tolerability demonstrated2 Sep 2022 13:08
Firstly I think we have cash til January.
Secondly say we don’t raise funds via;
AVA3996 licence.
Some kind of deal with LG or Daewoong (or further milestones)
Heading to Nasdaq.
Selling the diagnostics division
Some other kind of JV.
And for some moronic reason Avacta decide to fund raise before Data (I wholly can not see this because it would simply have no advantage to them at all) and we raise say £50m at a quid or so for a 20% dilution, then what would be the point of licensing ProValcade to Takeda? I think that’s the situation we’re in; if they want it it’s now or never for Takeda. It’s worth so much to them but £50m via a fund raise would take us to mid 2025 or so? Excluding milestone payments etc. it would allow us to take AVA6000 to market which would fund valcade and so therefore take a big chunk out of Takedas revenue. I just can’t see that happening. So I agree with RAH, that a license deal will come before data as they’ll certainly have an eye on it via our old friend, the NDA.